PLA2G2D Antagonist Enhances Immune Response in Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies face challenges in effectively treating cancers and viral infections due to immunosuppressive mechanisms mediated by the tumor and host immune system, particularly the PLA2G2D signaling pathway, which suppresses immune responses by inhibiting T cell proliferation and cytokine production.
Innovation Solution
Administering an antagonist targeting the PLA2G2D signaling pathway, such as an anti-PLA2G2D antibody or inhibitory PLA2G2D polypeptide, to inhibit PLA2G2D enzymatic activity or block its binding to immune cells, thereby enhancing immune cell activation and cytokine production in cancer or infection sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunotherapy is administered to treat cancer, then treatment efficacy is improved, but immunosuppressive mechanisms mediated by PLA2G2D suppress immune response and reduce effectiveness
Solution Approach 1:
The patent applies preliminary anti-action by administering a PLA2G2D antagonist before or concurrent with immunotherapy to prevent the immunosuppressive effects of PLA2G2D from occurring. The antagonist blocks PLA2G2D signaling pathway in advance, creating a favorable immune environment that enhances subsequent immunotherapy effectiveness.
Solution Approach 2:
The patent uses an intermediary substance (PLA2G2D antagonist) that mediates between the immunotherapy and the immune system. The antagonist binds to PLA2G2D or its receptors, preventing harmful interactions while allowing beneficial immunotherapy effects to proceed, thus enhancing overall treatment efficacy.
2Productivity
If PLA2G2D signaling pathway is active, then immune cell function is suppressed, but blocking this pathway enhances immune cell activation and cytokine production
Solution Approach 1:
The patent extracts or removes the harmful effect of PLA2G2D signaling by using an antagonist that specifically binds to PLA2G2D or its downstream components. This selective extraction of the pathogenic signaling pathway allows beneficial immune functions to proceed without suppression while maintaining normal physiological processes.
Solution Approach 2:
The patent changes the parameter of PLA2G2D signaling activity from active to inhibited state by introducing an antagonist. This parameter change reverses the suppressive effect on immune cells, transforming the immune microenvironment from immunosuppressive to immunostimulatory, thereby enhancing T cell proliferation and cytokine production.
Data Source
AI summary
The present application provides methods of treating a disease (such as cancer or infectious disease) that involves an antagonist that targets PLA2G2D signaling pathway (such as an antagonist that targets PLA2G2D. The present application also provides non-naturally occurring PLA2G2D polypeptides.